Scabies — classic & crusted (Norwegian)
DERMATOLOGY-framed scabies engine — owns the 2020 IACS diagnostic arc, the classic-vs-crusted split, the great-imitator pivot (scabies missed as steroid-worsened "treatment-resistant eczema"), the stepwise scabicide ladder, and the public-health arc (treat patient + ALL contacts + the environment; institutional/endemic MDA; post-streptococcal sequelae of secondary impetigo). Secondary bacterial sepsis is recognised here and routed OUT to the systemic-infection pathway. Guidelines refreshed (not merely tagged) 2026-05-18 via PubMed MCP: 2020 IACS criteria (PMID 32034956), European/JEADV 2017 management guideline (PMID 28639722), WHO Lancet control (PMID 31178154) + PLoS NTD framework (PMID 34473725), Cochrane permethrin/ivermectin (PMID 29608022), 2024 treatment-failure meta-analysis (PMID 37625798), crusted-scabies cohort (PMID 33338053), Fiji MDA RCT (PMID 26650152), microscopy/IACS validation (PMID 32255795, 33017426), MDA-impetigo (PMID 35345391). All cited PMIDs are PubMed-verified this session; the memory verified-floor sets no scabies-specific floor — recommend adding "Scabies: 2020 IACS criteria + European 2017 + WHO NTD framework" to the floor. RxCUIs validated live against RxNav 2026-05-18 (forward name→cui + reverse cui→RxNorm Name): permethrin 33199, ivermectin 6069, precipitated sulfur 10223 (clean ingredient "sulfur"; product-search 89767 reverse-resolves to "colloid sulfur"), benzyl benzoate 19044, crotamiton 21766, hydroxyzine 5553, cephalexin 2231, clindamycin 2582. No hand-authored codes. Non-pharm public-health entries (contact treatment, environmental decontamination, isolation, keratolytic bundle, MDA/notification) are non_pharm:true. Crusted-scabies grading (Hasan Grade 1/2/3 driving 3/5/7 ivermectin doses) and IACS certainty levels (A confirmed / B clinical / C suspected) are schema-blocked — not first-class TS calculators in the clinical-tools registry; captured narratively in RISK_STRATIFICATION/INITIAL_WORKUP. Decision surface satisfied by the 5-step regimen ladder + workup.chronic_pruritus + calc.ckd_epi_2021. Bayesian linkage (pruritic-dermatosis pre-test priors with context-shifted institutional prior, LR+/LR− for ≥8 distinguishing findings incl. the great-imitator pivot, ≥4 conditional dependencies — microscopy sensitivity | classic vs crusted, itch-onset LR | primary vs re-infestation, "failure" LR | post-scabetic vs persistence vs re-infestation vs resistance, dermoscopy | examiner expertise — T_treat/T_test empirical treat-the-contacts threshold, ≥4 cross-dossier routing edges by engine_id) is documented in the co-located _design-brief.md + _research-bundle.md; first-class TS LR fields remain schema-blocked (same constraint as the cellulitis/atopic-dermatitis gold templates). Effect sizes (≥10): permethrin wk1 clearance ~65% vs oral ivermectin single-dose ~43% (RR 0.65, 95% CI 0.54-0.78; Cochrane PMID 29608022), converging by wk2 (~74% vs ~68%; RR 0.91) and at 4 wk with 1-3 doses (~93% vs ~86%; RR 0.92); 2-dose vs single-dose ivermectin treatment failure 7.1% vs 15.2% (Mbuagbaw PMID 37625798); overall scabies treatment-failure prevalence 15.2% (95% CI 12.9-17.6), rising ~0.27%/yr (permethrin ~0.58%/yr); ivermectin MDA reduced community scabies prevalence 32.1%→1.9% (relative reduction 94%, 95% CI 83-100) and impetigo 24.6%→8.0% (67%) at 12 mo vs permethrin-MDA 62% and standard-care 49% (Romani NEJM 2015 PMID 26650152); MDA cut SSTI hospitalisations 17% (IRR 0.83) and impetigo prevalence 15.3%→6.1% (PR 0.40; Thean PMID 35345391); microscopy sensitivity 100% confirmed / 73% across confirmed+clinical+suspected, PCR ~80-86%, specificity 100% (Bae PMID 32255795); IACS non-expert examiner sensitivity 69-83%, specificity 70-96% (Walker PMID 33017426); crusted-scabies cohort 38%/39%/23% Grade 1/2/3, eosinophilia 60%, raised IgE 94%, bacteraemia in 11 episodes with one MSSA fatality (Hasan PMID 33338053). Full numerics + DOIs in _research-bundle.md.
Entry points (5)
- symptomIntense, generalised, nocturnally-worse pruritus (delayed type-IV hypersensitivity to the mite — onset ~3-6 wk in primary infestation, days on re-infestation) (2020 IACS criteria PMID 32034956; European guideline PMID 28639722)intense_nocturnal_generalised_pruritus
- symptomBurrows + papules in finger web-spaces / flexor wrists / axillae / periumbilical / genital (penile/scrotal nodules) / areolae — classic scabies distribution (2020 IACS criteria PMID 32034956)burrows_webspace_genital_papules
- historyItchy household / sexual / close contacts or an institutional cluster — the single strongest contextual pointer (European guideline PMID 28639722; WHO control PMID 31178154)affected_close_or_household_contacts
- symptomHyperkeratotic, crusted, scaly plaques (± reduced/absent itch) in an immunocompromised / HIV / HTLV-1 / elderly / institutionalised / neurologic host → crusted (Norwegian) scabies (European guideline PMID 28639722; Hasan PLoS NTD 2020 PMID 33338053)hyperkeratotic_crusted_plaques_immunocompromised
- history"Treatment-resistant eczema" worsening on topical/systemic steroids → the great-imitator entry; route from derm.atopic-dermatitis.core.v1 (2020 IACS criteria PMID 32034956)steroid_refractory_treatment_resistant_eczema
Required inputs (15)
- itch_pattern_and_timingrequiredsymptom • used at ENTRYGeneralised nocturnal itch out of proportion to visible rash, with the characteristic onset lag (~3-6 wk primary; days on re-infestation), is the central symptom and shapes the pre/post-treatment itch-trajectory counselling (2020 IACS criteria PMID 32034956)
- lesion_distribution_and_burrowsrequiredsymptom • used at CONTEXTWeb-space/wrist/axilla/periumbilical/genital burrows + papules support IACS clinical/confirmed levels; scalp/face involvement reframes toward infant/elderly/crusted disease (2020 IACS criteria PMID 32034956; community validation PMID 33017426)
- close_contact_and_institutional_contextrequiredhistory • used at CONTEXTAffected household/sexual/close contacts and institutional residence (aged-care, shelter, prison) raise the pre-test probability strongly and trigger the contact-tracing + outbreak arc (European guideline PMID 28639722; WHO framework PMID 34473725)
- immunocompromise_or_crusted_riskrequiredhistory • used at CONTEXTHIV / HTLV-1 / haematologic / iatrogenic immunosuppression / elderly / neurologic-cognitive impairment predicts crusted scabies (hyperinfestation), the distinct intensive regimen, and outbreak risk (Hasan PLoS NTD 2020 PMID 33338053; European guideline PMID 28639722)
- secondary_bacterial_infection_signsrequiredsymptom • used at RED_FLAGSHoney-crust / pustules / impetiginisation → Staphylococcus aureus / Streptococcus pyogenes secondary infection; in endemic settings carries post-streptococcal GN / rheumatic-fever sequelae and crusted-scabies sepsis risk (MDA-impetigo trial PMID 35345391; Hasan PMID 33338053)
- crusted_scabies_severity_gradesymptom • used at RISK_STRATIFICATIONCrusted-scabies grade (distribution/crust thickness/prior episodes — Grade 1/2/3) drives the number of ivermectin doses (3 vs 5 vs 7) and isolation intensity (Hasan PLoS NTD 2020 PMID 33338053 — schema-blocked grading captured narratively)
- dermoscopy_or_microscopy_confirmationimaging • used at INITIAL_WORKUPDermoscopy ("delta-wing-jet"/burrow sign) or skin-scraping/ink-burrow microscopy moves the diagnosis from IACS suspected/clinical to confirmed; microscopy is specific but insensitive in classic disease (2020 IACS PMID 32034956; microscopy/PCR PMID 32255795)
- pregnancy_lactationhistory • used at TREATMENTPermethrin or precipitated sulfur preferred in pregnancy/lactation; oral ivermectin generally avoided — gates the scabicide ladder (European guideline PMID 28639722)
- age_and_weightrequireddemographic • used at TREATMENTNeonates/infants <2 mo → precipitated sulfur (permethrin/ivermectin cautioned); ivermectin generally avoided if weight <15 kg; scalp/face must be treated in infants and the elderly; weight-based ivermectin dosing (European guideline PMID 28639722; WHO control PMID 31178154)
- household_and_sexual_contacts_for_treatmentrequiredhistory • used at TREATMENTALL close/household/sexual contacts (even asymptomatic) must be treated simultaneously with a 2-month partner look-back, or re-infestation is near-certain (European guideline PMID 28639722)
- prior_scabicide_adequacy_and_adherencerequiredhistory • used at MONITORINGApparent "treatment failure" is usually post-scabetic itch, re-infestation from untreated contacts, or mis-application — true persistence/resistance is a diagnosis of exclusion (2024 treatment-failure meta-analysis PMID 37625798)
- endemic_or_resource_limited_settinghistory • used at DISPOSITIONHigh-prevalence/endemic or institutional-outbreak context shifts management toward ivermectin mass drug administration and post-streptococcal-sequelae vigilance (WHO control PMID 31178154; WHO framework PMID 34473725; MDA trial PMID 26650152)
- cbc_eosinophilialab • used at INITIAL_WORKUPEosinophilia + markedly raised IgE are common in crusted scabies and support hyperinfestation; CBC also screens for secondary bacterial sepsis (Hasan PLoS NTD 2020 PMID 33338053)
- inflammatory_markerslab • used at RED_FLAGSCRP/inflammatory markers track secondary bacterial superinfection / crusted-scabies sepsis severity (Hasan PLoS NTD 2020 PMID 33338053)
- creatininelab • used at TREATMENTRenal function (race-free CKD-EPI 2021) where comorbid CKD/dialysis informs supportive dosing in crusted-scabies inpatients (Hasan PLoS NTD 2020 PMID 33338053 — 23% on dialysis; Inker NEJM 2021)
12-phase flow (12)
- 1FRAMEFrame as a Sarcoptes scabiei infestation with an IMMUNOLOGIC (delayed type-IV) itch that lags infestation by weeks — so itch timing, post-scabetic persistence, and "the whole household + the environment, not just the patient" define management. The great-imitator trap (missed as steroid-worsened eczema) and the classic-vs-crusted split (hyperinfestation, outbreak, sepsis) are set here.advance: scabies frame set; classic-vs-crusted + great-imitator + contact/public-health escape routes noted
- 2ENTRYRecognise intense nocturnally-worse generalised pruritus with web-space/genital burrows, the affected-contacts/institutional entry, the crusted-host entry, or the steroid-refractory-eczema great-imitator entry; capture the itch pattern + onset-lag up front.inputs: itch_pattern_and_timingactions: workup.chronic_pruritusadvance: entry trigger present; itch pattern + timing recorded
- 3CONTEXTBuild the diagnostic + public-health context: classic distribution and burrows (IACS lesion criteria), affected close/household/sexual contacts and institutional residence (the strongest contextual prior + the contact-tracing trigger), and immunocompromise / elderly / neurologic status (crusted-scabies + outbreak risk).inputs: lesion_distribution_and_burrows, close_contact_and_institutional_context, immunocompromise_or_crusted_riskactions: workup.chronic_pruritusadvance: IACS clinical level supportable; contact + crusted-risk context established
- 4RED_FLAGSSecondary bacterial infection (honey-crust / pustules / impetiginisation → S. aureus / S. pyogenes) — in crusted scabies a sepsis/bacteraemia source; in endemic settings carries post-streptococcal glomerulonephritis / rheumatic-fever sequelae. Crusted scabies itself is a transmissibility + morbidity red flag (isolation + outbreak control). Institutional cluster → public-health notification.inputs: secondary_bacterial_infection_signs, inflammatory_markersactions: panel.cbc, panel.inflammationadvance: impetiginisation / crusted-sepsis / outbreak screened and escalated/notified if present
- 5INITIAL_WORKUPScabies is largely a clinical diagnosis under the 2020 IACS criteria. Targeted confirmation: dermoscopy ("delta-wing-jet"/burrow sign — high yield, non-invasive), skin-scraping or burrow-ink microscopy (specific but insensitive in classic disease — high mite load makes crusted scabies easy to confirm), biopsy if atypical/CTCL-mimic in the immunocompromised. CBC for eosinophilia/IgE (crusted) and to screen secondary sepsis.inputs: dermoscopy_or_microscopy_confirmation, cbc_eosinophiliaactions: panel.cbc, panel.lftadvance: IACS certainty level assigned (confirmed/clinical/suspected); confirmatory test done if indicated
- 6BRANCHING_WORKUPPruritic-dermatosis decision tree: burrows + web-space + affected contacts + nocturnal itch + no atopy → scabies; flexural + atopic diathesis + no burrows/contacts and improves on steroids → atopic dermatitis (route derm.atopic-dermatitis.core.v1 — the dominant misdiagnosis); geometric/exposure-mapped → contact dermatitis (route derm.contact-dermatitis.core.v1); new-drug-linked widespread pruritus → drug eruption (route derm.drug-eruption.core.v1); grouped vesicles + gluten/IgA → dermatitis herpetiformis; grouped excoriated papules without burrows → papular urticaria/insect bites; nits/lice → pediculosis; hyperkeratotic mimic in HIV → exclude CTCL/crusted overlap by biopsy.inputs: steroid_refractory_treatment_resistant_eczemaactions: workup.chronic_pruritusadvance: scabies confirmed/clinically assigned OR an alternative dermatosis assigned + routed by engine_id
- 7DIFFERENTIALTerminal pruritic differential with named pivots: scabies vs atopic dermatitis (burrows + web-space + affected contacts + nocturnal itch + worsens-on-steroids pivot — route derm.atopic-dermatitis.core.v1) vs contact dermatitis (geometric/exposure-mapped pivot — route derm.contact-dermatitis.core.v1) vs dermatitis herpetiformis (grouped vesicles + extensor + IgA/gluten pivot) vs papular urticaria/insect bites (grouped urticarial papules, no burrows pivot) vs prurigo nodularis (chronic isolated nodules pivot) vs pediculosis (nits/lice pivot) vs asteatotic/xerotic eczema (dry crazy-paving, elderly winter pivot) vs cutaneous T-cell lymphoma (fixed poikilodermatous, crusted-mimic in immunocompromised — biopsy pivot) vs drug eruption (new-drug timeline pivot — route derm.drug-eruption.core.v1).advance: single best diagnosis selected; great-imitator (eczema) actively excluded; crusted-vs-CTCL biopsied in the immunocompromised mimic
- 8RISK_STRATIFICATIONStratify classic vs crusted (Norwegian) and grade severity: classic (~10-15 mites, outpatient) vs crusted Grade 1/2/3 (Hasan distribution/crust/recurrence grading — schema-blocked, narrated) which scales the ivermectin dose count (3/5/7), the isolation intensity, and the outbreak-control footprint. Layer secondary-sepsis risk, immunocompromise depth, and institutional-cluster scale.inputs: crusted_scabies_severity_grade, immunocompromise_or_crusted_riskadvance: classic-vs-crusted + crusted grade + sepsis/outbreak modifier assigned
- 9TREATMENTTREAT THE PATIENT + ALL CONTACTS + THE ENVIRONMENT, never the patient alone. Classic: permethrin 5% whole-body neck-down (scalp/face also in infants/elderly/crusted), wash off 8-14 h, REPEAT day 7-14; or oral ivermectin 200 mcg/kg day 1 + day 8 (preferred for outbreaks/when topical impractical). Alternatives: benzyl benzoate, precipitated sulfur (pregnancy/neonatal-safe <2 mo), crotamiton (lower efficacy). Crusted scabies: combined multi-dose oral ivermectin (Grade 1/2/3 → 3/5/7 doses, e.g. d1,2,8,9,15±22,29) + daily topical scabicide + keratolytic + strict isolation + environmental decontamination. Adjuncts: simultaneous contact treatment (2-month look-back), environmental decontamination (hot-wash/hot-dry/seal-bag 72 h), anti-staphylococcal cover if impetiginised (with post-streptococcal-sequelae vigilance in endemic settings), and explicit POST-SCABETIC-ITCH management with topical steroid/antihistamine — counselled as expected, NOT failure. Gating: pregnancy/lactation → permethrin or sulfur; <2 mo or <15 kg → sulfur (avoid ivermectin); crusted → isolate + barrier; do NOT treat as eczema with steroids alone.inputs: pregnancy_lactation, age_and_weight, household_and_sexual_contacts_for_treatment, creatinineadvance: scabicide + repeat dose + simultaneous contact treatment + environmental decontamination + post-scabetic-itch counselling all defined; crusted regimen intensified if applicable
- 10DISPOSITIONClassic scabies is outpatient: treat, contact-trace, decontaminate, counsel post-scabetic itch, 2- and 4-week recheck. Crusted scabies / secondary sepsis / institutional outbreak → inpatient isolation (barrier nursing) with combined regimen and route secondary sepsis OUT to the systemic-infection pathway; institutional/endemic cluster → public-health notification + mass drug administration consideration (cohort treatment of the whole facility/community).inputs: endemic_or_resource_limited_setting, secondary_bacterial_infection_signsadvance: disposition documented; crusted/outbreak admitted+isolated+notified; classic discharged with full contact+environment plan
- 11MONITORINGSet itch-trajectory expectations BEFORE discharge: post-scabetic pruritus may persist 2-4 wk after successful eradication and is NOT failure — manage with emollient/topical steroid/antihistamine, do not re-treat reflexively. Reassess at 2 and 4 wk. Apparent failure → structured workup: (1) re-infestation from an untreated contact (commonest), (2) non-adherence/mis-application, (3) post-scabetic itch misread, (4) wrong diagnosis, then (5) true persistence/resistance (rising over time per the 2024 meta-analysis) — escalate dose/agent only after 1-4 excluded.inputs: prior_scabicide_adequacy_and_adherenceactions: workup.chronic_pruritusadvance: itch-trajectory counselled; 2/4-wk recheck booked; failure workup structured before any re-treatment
- 12FOLLOWUPConfirm eradication at ~4 wk; ensure ALL contacts were treated (untreated contacts = the dominant recurrence driver); reinforce environmental decontamination; in endemic/institutional settings arrange surveillance, MDA linkage, and post-streptococcal-sequelae follow-up after secondary impetigo (urinalysis/BP for post-strep GN). Crusted scabies: relapse is common on return to an endemic community — plan repeat-screening and a low threshold to re-treat the index + cohort.inputs: endemic_or_resource_limited_setting, household_and_sexual_contacts_for_treatmentactions: workup.chronic_pruritusadvance: eradication confirmed; contact + environment completion verified; endemic/crusted surveillance + post-strep-sequelae follow-up arranged